The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment…

On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech…

Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed…

Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi's out-licensing of a potential COVID-19 treatment to…

Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being…